Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Genes, Chromosomes & Cancer|December 4, 2002
A novel chromosomal inversion at 11q23 in infant acute myeloid leukemia fuses MLL to CALM, a gene that encodes a clathrin assembly proteinDaniel S Wechsler, Lars D Engstrom, Brian M Alexander, et al.
Cancer Immunology, Immunotherapy : CII|November 11, 2017
The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapyDavid Briere, Niranjan Sudhakar, David M Woods, et al.
Neoplasia (New York, N.Y.)|November 19, 2004
Mxi1-0, an alternatively transcribed Mxi1 isoform, is overexpressed in glioblastomasLars D Engstrom, Andrew S Youkilis, Judith L Gorelick, et al.
Molecular Cancer Therapeutics|March 16, 2021
The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor TherapyDavid M Briere, Shuai Li, Andrew Calinisan, et al.
Molecular Cancer Therapeutics|March 6, 2012
Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitorHelen Y Zou, Qiuhua Li, Joseph H Lee, et al.
Bioorganic & Medicinal Chemistry|August 4, 2022
Design and evaluation of achiral, non-atropisomeric 4-(aminomethyl)phthalazin-1(2H)-one derivatives as novel PRMT5/MTA inhibitorsChristopher R Smith, Ruth Aranda, James G Christensen, et al.
Journal of Medicinal Chemistry|January 18, 2022
Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of MTAP-Deleted CancersChristopher R Smith, Ruth Aranda, Thomas P Bobinski, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 4, 2015
PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutationsHelen Y Zou, Qiuhua Li, Lars D Engstrom, et al.
Cancer Research|July 22, 2025
Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic CancerKristina Drizyte-Miller, Lars D Engstrom, Jeffrey A Klomp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2017
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical ModelsLars D Engstrom, Ruth Aranda, Matthew Lee, et al.
Pageof 2